Pfizer Oncology has a longstanding commitment to the pursuit of life-changing breakthroughs. By placing patients and collaboration at the centre of everything we do, we believe we can have a meaningful impact on the lives of cancer patients. Both now, and in the future.
Every day, around 1,000 people are diagnosed with cancer in the UK.1 But, thanks to innovative treatment breakthroughs and significant advances in our understanding of the disease, more people than ever are surviving cancer.2
At Pfizer Oncology, we have an industry-leading portfolio of more than 20 approved innovative cancer medicines and biosimilars across over 30 indications, including melanoma, breast, genitourinary, colorectal, blood and lung cancers.3
We've made meaningful progress - but our work is far from finished. Currently, there are 130 Pfizer-sponsored Oncology clinical trials, with studies spanning more than 20 different tumour types and subtypes.4
At Pfizer UK, we are proud of our long history of successfully partnering with organisations that share our purpose to deliver the right treatment for each patient at the right time. We also partner with scientists, academics and clinicians, to share knowledge, skills and expertise, with the aim to improve the health and lives of people in the UK and around the world.
Over the past 70 years, we have continued to invest in the UK and are committed to working with the National Health Service (NHS) and other healthcare organisations across the industry, developing solutions to improve the delivery of care and patient outcomes. The NHS has access to over 150 Pfizer medicines and vaccines that are delivered to pharmacies, surgeries, and hospitals across the UK every day.5
We also partner with relevant policy-makers and other stakeholders driven by our purpose: Breakthroughs that change patients' lives.
Patients are now - more than ever - equipped, informed and empowered to define healthcare in their own terms. At Pfizer, we recognise the importance of harnessing the power of patient experiences to understand what healthcare means to the individual. Through our commitment to working together, we aim to personalise patient care and deliver better healthcare for the people that matter most - patients.6
Patient centricity within Pfizer Oncology is a longstanding tradition. Over the years, our team has cultivated relationships with many patient advocates across the world - with the common goals of ensuring health equity and literacy for all, and supporting patient engagement in clinical trials.
In 2019, to expand these efforts and further embed patient insights and experiences into all activities, Pfizer Oncology launched an initiative to create a Patient Centric Ecosystem (POPCE). Today, this ecosystem is continuing to yield actionable insights, providing opportunities for information-sharing and partnership across the cancer community.4
At Pfizer, we are relentless in our pursuit of medicines and vaccines that will benefit patients around the world, and our product pipeline has never been stronger. By 2025, we are committed to treating 225 million people with breakthrough therapies.
In addition to our medicines, we are also supporting patients through innovative technologies, such as the ByYourSideTM app, a digital support programme designed specifically to help people living with cancer, as well as their friends and family members.7
In the UK, our investment goes beyond our medicines. We are investing in the future by supporting the scientists of tomorrow, through the UK's National Apprenticeship Programme, our undergraduate placement scheme and various STEM (Science, Technology, Engineering and Mathematics) and SIP (Science Industry Partnership) activities.5
1. Cancer Research UK. Cancer incidence statistics. Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence#heading-Zero [Last accessed: May 2022].
2. Maddams J, Utley M, Møller H. Projections of cancer prevalence in the United Kingdom, 2010-2040. Br J Cancer 2012; 107 (7):1195-202.
3. Pfizer press release. Pfizer Completes Acquisition of Trillium Therapeutics. November 2021. Available at: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-trillium-therapeutics [Last accessed May 2022].
4. Pfizer Oncology Patient Centricity Ecosystem: From Launch to Impact. Available at: https://cdn.pfizer.com/pfizercom/Pfizer_APR_WhitePaper_080921.pdf [Last accessed: May 2022].
5. Pfizer.com Pfizer in the UK. April 2022. Available at: https://www.pfizer.co.uk/our-science/pfizer-uk [Last accessed: May 2022].
6. Pfizer press release. Working with Patient Organisations. Available at: https://www.pfizer.co.uk/uk-health-system/working-with-patient-organisations [Last accessed: May 2022].
7. Pfizer press release. ByYourSide App and Website launched to help cancer patients in need. Available at: https://www.pfizer.co.uk/news-and-featured-stories/byyourside-app-and-website-launched-to-help-cancer-patients-in-need [Last accessed: May 2022]
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021
Add indication message here. It can link a link,
and you can EMBOLDEN text
OK, We will need you to sign in before we can determine if you are aligned with a Pﬁzer promotional colleague.
If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.
Would you like to register or sign in now?